SCHEMBL20404615

SCHEMBL20404615

Cc1ccc(CN(C)CC(O)c2cccc([N+](=O)[O-])c2)c(C)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.56
MEN1 O00255 3/20 0.56
L3MBTL1 Q9Y468 2/20 0.56
HPGD P15428 1/20 0.56
TSHR P16473 1/20 0.43
ACHE P22303 1/20 0.43
HTT P42858 2/20 0.42
LMNA P02545 3/20 0.40
TAAR1 Q96RJ0 1/20 0.40
PYCR1 P32322 2/20 0.40
POLB P06746 1/20 0.39
ACP3 P15309 1/20 0.38
CYP3A4 P08684 2/20 0.37
CYP2D6 P10635 2/20 0.37
SLC6A2 P23975 1/20 0.37
SLC6A4 P31645 1/20 0.37
SLC6A3 Q01959 1/20 0.37
NFE2L2 Q16236 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2568705 0.81 MEN1 (0.55) KMT2AMEN1L3MBTL1HPGDHTT
SCHEMBL28546709 0.80 PYCR1 (0.44) KMT2AMEN1TAAR1PYCR1SLC6A2
SCHEMBL30435410 0.80 PYCR1 (0.44) KMT2AMEN1TAAR1PYCR1SLC6A2
SCHEMBL6898173 0.71 L3MBTL1 (0.65) KMT2AMEN1L3MBTL1HPGDTSHR
SCHEMBL2509178 0.71 L3MBTL1 (0.65) KMT2AMEN1L3MBTL1HPGDTSHR
SCHEMBL1983563 0.70 L3MBTL1 (0.64) KMT2AMEN1L3MBTL1HPGDTSHR
SCHEMBL2367944 0.70 L3MBTL1 (0.64) KMT2AMEN1L3MBTL1HPGDTSHR
SCHEMBL28555041 0.70 PYCR1 (0.43) KMT2AMEN1HPGDLMNATAAR1
SCHEMBL30435138 0.70 PYCR1 (0.43) KMT2AMEN1HPGDLMNATAAR1
SCHEMBL12237260 0.69 KMT2A (0.56) KMT2AMEN1L3MBTL1HPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3351248-A1 COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS Ardelyx, Inc. (US) 2018-07-25 EP disclosed